Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Predictive Oncology ( (POAI) ).
On September 19, 2025, Predictive Oncology‘s stockholders approved a one-for-fifteen reverse stock split to comply with Nasdaq’s minimum bid price requirement. The reverse stock split, effective September 29, 2025, will reduce the number of outstanding shares and begin trading on a split-adjusted basis on September 30, 2025. This move aims to maintain the company’s listing on the Nasdaq Capital Market.
The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including declining revenues and negative profit margins. The technical analysis indicates a bearish trend, and the valuation reflects ongoing losses with no dividend yield. Additionally, the risk of delisting due to Nasdaq non-compliance further pressures the stock’s outlook.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Predictive Oncology is a leader in AI-driven drug development and discovery, focusing on expediting early drug discovery and enabling drug development for cancer patients worldwide. The company utilizes its scientifically validated AI platform, PEDAL, which predicts tumor response to drug compounds with high accuracy, and maintains a vast biobank of human tumor samples. It is headquartered in Pittsburgh, PA.
Average Trading Volume: 190,484
Technical Sentiment Signal: Hold
Current Market Cap: $12.85M
Find detailed analytics on POAI stock on TipRanks’ Stock Analysis page.